Crossmark

Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> ‐L1/ <scp>PD</scp> ‐1 blockade therapy

Crossref DOI link: https://doi.org/10.15252/emmm.201910293

Published Online: 2019-06-06

Published Print: 2019-07

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Zuazo, Miren

Arasanz, Hugo

Fernández‐Hinojal, Gonzalo

García‐Granda, Maria Jesus

Gato, María

Bocanegra, Ana

Martínez, Maite

Hernández, Berta

Teijeira, Lucía

Morilla, Idoia

Lecumberri, Maria Jose

Fernández de Lascoiti, Angela

Vera, Ruth https://orcid.org/0000-0003-1524-3147
Kochan, Grazyna https://orcid.org/0000-0002-0534-9661
Escors, David https://orcid.org/0000-0003-2828-4458
Funding

Funding for this research was provided by:

Fundación Científica Asociación Española Contra el Cáncer (PROYE16001ESCO)

Instituto de Salud Carlos III (PI17/02119)

Instituto de Salud Carlos III (CP12/03114)

Fundación Española para la Ciencia y la Tecnología (PRECIPITA)
License Information

Version of Record valid from 2019-06-06
More Information

Publication History

Received: 2019-01-09

Accepted: 2019-05-14

Published: 2019-06-06